Serving leading biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving leading biopharmaceutical companies globally:
Generated: October 21, 2017
What is the competitive landscape for BRISTOL, and what generic alternatives to BRISTOL drugs are available?
BRISTOL has one hundred and ten approved drugs.| International Patents: | 663 |
| US Patents: | 24 |
| Tradenames: | 87 |
| Ingredients: | 74 |
| NDAs: | 110 |
| Drug Master File Entries: (click here to view) | 1 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
apixaban | Tablets | 2.5 mg and 5 mg | ELIQUIS | 12/28/2016 |
efavirenz | Capsules | 50 mg, 100 mg and 200 mg | SUSTIVA | 11/3/2016 |
naloxone hydrochloride | Nasal Spray | 4 mg/spray | NARCAN | 7/15/2016 |
dasatinib | Tablets | 80 mg and 140 mg | SPRYCEL | 6/17/2011 |
dasatinib | Tablets | 80 mg and 140 mg | SPRYCEL | 6/16/2011 |
dasatinib | Tablets | 20 mg, 50 mg, 70 mg and 100 mg | SPRYCEL | 6/28/2010 |
entecavir | Tablets | 0.5 mg and 1 mg | BARACLUDE | 6/14/2010 |
atazanavir sulfate | Capsules | 100 mg and 150 mg | REYATAZ | 3/19/2010 |
atazanavir sulfate | Capsules | 200 mg | REYATAZ | 2/16/2010 |
atazanavir sulfate | Capsules | 300 mg | REYATAZ | 7/20/2009 |
efavirenz | Tablets | 600 mg | SUSTIVA | 4/9/2009 |
pravastatin sodium | Tablets | 30 mg | PRAVACHOL | 6/1/2005 |
didanosine | Delayed-release Capsules | 200 mg, 250 mg and 400 mg | VIDEX EC | 6/1/2004 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6,673,810 | Imidazo-heterobicycles as factor Xa inhibitors | ► Subscribe | |||||||||||||
| 7,005,435 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | ► Subscribe | |||||||||||||
| 6,989,391 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | ► Subscribe | |||||||||||||
| 5,965,729 | Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent | ► Subscribe | |||||||||||||
| 7,371,761 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | ► Subscribe | |||||||||||||
| 6,110,946 | Antivirally active heterocyclic azahexane derivatives | ► Subscribe | |||||||||||||
| 7,939,553 | Modulators of pharmacokinetic properties of therapeutics | ► Subscribe | |||||||||||||
| 7,091,223 | Cyclic protein tyrosine kinase inhibitors | ► Subscribe | |||||||||||||
| 8,188,120 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | ► Subscribe | |||||||||||||
| 7,531,535 | Lactam-containing compounds and derivatives thereof as factor Xa inhibitors | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| European Patent Office | 2385048 | ► Subscribe | |||||||||||||
| Cyprus | 1118232 | ► Subscribe | |||||||||||||
| Poland | 334478 | ► Subscribe | |||||||||||||
| Cyprus | 1116688 | ► Subscribe | |||||||||||||
| Austria | 439360 | ► Subscribe | |||||||||||||
| Slovenia | 2487163 | ► Subscribe | |||||||||||||
| Australia | 2005304863 | ► Subscribe | |||||||||||||
| Luxembourg | 92864 | ► Subscribe | |||||||||||||
| Israel | 144910 | ► Subscribe | |||||||||||||
| Spain | 2181417 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| /2004 | Austria | ► Subscribe | PRODUCT NAME: DROSPIRENON IN KOMBINATION MIT ESTRADIOL; NAT. REGISTRATION NO/DATE: 1-25178, 1-25179 20031127; FIRST REGISTRATION: NL RVG 27505 20021211 | ||||||||||||
| 00597 | Netherlands | ► Subscribe | PRODUCT NAME: INSULINE DEGLUDEC EN INSULINE ASPART; REGISTRATION NO/DATE: EU/1/12/806/001EU/1/12/806/004EU/1/12/806/005EU/1/12/806/007EU/1/12/806/008 2013210121 | ||||||||||||
| 401 | Luxembourg | ► Subscribe | PRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE | ||||||||||||
| 2013025,C1304992 | Lithuania | ► Subscribe | PRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323 | ||||||||||||
| C0005 | Belgium | ► Subscribe | PRODUCT NAME: ESTRADIOL HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: 298 IS 190 F 15 19960806; FIRST REGISTRATION: GB PL/0053/0241 19950711 | ||||||||||||
| 11/032 | Ireland | ► Subscribe | PRODUCT NAME: APIXABAN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/11/691/001-005 20110518 | ||||||||||||
| 888 | Luxembourg | ► Subscribe | 91888, EXPIRES: 20260518 | ||||||||||||
| 00C/027 | Belgium | ► Subscribe | PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124 | ||||||||||||
| 91022-0 | Sweden | ► Subscribe | PRODUCT NAME: N EPSILONB29 MYRISTOYL- ELLER N EPSILONB29 TETRADEKANOYL-DES(B30) HUMANT INSULIN | ||||||||||||
| 90036-0 | Sweden | ► Subscribe | PRODUCT NAME: KOMBINATION AV INSULIN DEGLUDEK OCH INSULIN ASPART; REG. NO/DATE: EU/1/12/806/001 20130121 | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,980 others who get our Drug Patent Expiration Alerts:
